Oral antidiabetic agents in gestational diabetes: a narrative review of current evidence.

Oral antidiabetic agents in gestational diabetes: a narrative review of current evidence. Expert Rev Endocrinol Metab. 2015 Mar;10(2):211-225 Authors: Singh AK, Singh R Abstract Gestational diabetes mellitus (GDM) classically occurs when maternal glucose metabolism is unable to compensate the progressive development of insulin resistance that arises from the continuously rising diabetogenic placental hormones. Although most women can be treated satisfactorily with diet alone, some require more intensive treatment. Insulin has been the most reliable treatment strategy in GDM over several decades. Although a long time has passed since the publication of two randomized controlled trials suggesting comparable efficacy and safety of metformin and glibenclamide, international bodies have not yet approved these oral agents. However, with the consistently emerging efficacy and safety data of these two drugs in the past decade, they may perhaps open a rather new door. The aim of this narrative review is to critically evaluate the existing evidence regarding safety and efficacy of oral drugs in GDM accumulated since the first publication in year 2000, suggesting clinical equivalency of glibenclamide (glyburide). PMID: 30293509 [PubMed]
Source: Expert Review of Endocrinology and Metabolism - Category: Endocrinology Tags: Expert Rev Endocrinol Metab Source Type: research